News coverage about Enzo Biochem (NYSE:ENZ) has been trending somewhat positive on Wednesday, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Enzo Biochem earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 45.6042631932165 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the headlines that may have effected Accern Sentiment’s rankings:

A number of brokerages have issued reports on ENZ. BidaskClub lowered shares of Enzo Biochem from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Zacks Investment Research lowered shares of Enzo Biochem from a “buy” rating to a “hold” rating in a research note on Tuesday, August 15th.

Shares of Enzo Biochem (NYSE ENZ) traded down 0.97% on Wednesday, reaching $11.19. 53,384 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $11.17 and a 200 day moving average of $9.51. The firm has a market capitalization of $519.29 million, a P/E ratio of 15.69 and a beta of 0.92. Enzo Biochem has a one year low of $4.88 and a one year high of $12.04.

COPYRIGHT VIOLATION NOTICE: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/06/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-enzo-biochem-enz-stock-price.html.

About Enzo Biochem

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Insider Buying and Selling by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Stock Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related stocks with our FREE daily email newsletter.